{"id":812240,"date":"2025-02-12T15:47:49","date_gmt":"2025-02-12T20:47:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/"},"modified":"2025-02-12T15:47:49","modified_gmt":"2025-02-12T20:47:49","slug":"investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/","title":{"rendered":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, Feb.  12, 2025  (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (\u201cIntellia\u201d or the \u201cCompany\u201d) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia\u2019s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.<\/p>\n<p align=\"justify\">If you bought shares of Intellia between <strong>July 30, 2024 and January 8, 2025<\/strong>, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JdLQ7xfRszVH2xWKDCO8Qh8v7G4EQTb2xuCh_BqW5O9soG5I5EAko0Z3epQD7pym3njKlaAXK1ghdyG5yewnrl8Q4xwI62g-mJdnEA3cR3A=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a>, by toll-free telephone at (888) 508-6832 or you may visit the firm\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4vryvtGYSmCmXOHzgiuTtbEazC8pNTJHdlhtRzp4XRA-3AIjOodOnUX449iHzdurUQeKTR8oDUlk0cRszjGVx055OnLkw5VpC0rZRm1WmoE13s_lp3cENdJpnYQ7dvu6-WTT564wEOlLzFAcaC_QxwXmjpuS28VUcp9raJgI0-8=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/intellia-therapeutics\/<\/a> to learn more.<\/p>\n<p align=\"justify\">\n        <strong>The deadline to ask the court to be appointed lead plaintiff in the case is April 14, 2025.<\/strong>\n      <\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4vryvtGYSmCmXOHzgiuTteJUOYeShLnUAwSFUqUH0cVrUE5jVxc9eraLyrJbK4dsxAJ12ikmnE6sPvsWlgDN4EOVGTBKDiNfCyNEAh_r-EQ=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com<\/a>, and upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JdLQ7xfRszVH2xWKDCO8Qh8v7G4EQTb2xuCh_BqW5O_1_DCYCvjjihgDeylBK7I7IgazYKPcg2hkonHkz-TR3v6nkUVT1yTgbpKNVOuNg6A=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmFjMDg5NTktNGU4OC00ZThkLWI5YjMtOThjYzdmNDBmYTNhLTExOTIzMzY=\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (\u201cIntellia\u201d or the \u201cCompany\u201d) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia\u2019s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. If you bought shares of Intellia between July 30, 2024 and January 8, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm\u2019s website at www.holzerlaw.com\/case\/intellia-therapeutics\/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-812240","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (\u201cIntellia\u201d or the \u201cCompany\u201d) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia\u2019s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. If you bought shares of Intellia between July 30, 2024 and January 8, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm\u2019s website at www.holzerlaw.com\/case\/intellia-therapeutics\/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the &hellip; Continue reading &quot;INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T20:47:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\",\"datePublished\":\"2025-02-12T20:47:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/\"},\"wordCount\":264,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/\",\"name\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\",\"datePublished\":\"2025-02-12T20:47:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","og_description":"ATLANTA, Feb. 12, 2025 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (\u201cIntellia\u201d or the \u201cCompany\u201d) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia\u2019s Phase 1\/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. If you bought shares of Intellia between July 30, 2024 and January 8, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm\u2019s website at www.holzerlaw.com\/case\/intellia-therapeutics\/ to learn more. The deadline to ask the court to be appointed lead plaintiff in the &hellip; Continue reading \"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-12T20:47:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm","datePublished":"2025-02-12T20:47:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/"},"wordCount":264,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/","name":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=","datePublished":"2025-02-12T20:47:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NzU1MiM2NzQ4NzI0IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-class-action-lawsuit-filed-on-behalf-of-intellia-therapeutics-inc-ntla-investors-holzer-holzer-llc-encourages-investors-with-significant-losses-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Intellia Therapeutics, Inc. (NTLA) Investors \u2013 Holzer &amp; Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=812240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/812240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=812240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=812240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=812240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}